Vaccine
Talk
(Egyptian Edition)
"Everything you need to know about
vaccines in Egypt"
Vaccine
Meningococcal
Three types of meningococcal vaccines: meningococcal conjugate (MenACWY), meningococcal polysaccharide (MPSV4), and serogroup B meningococcal (MenB) vaccines.
Persons with functional or anatomic asplenia (including sickle cell disease), HIV infection and persistent complement component deficiency (including persons taking eculizumab [Soliris]) are at increased risk for meningococcal disease and should receive MenACWY vaccine.
Persons with functional or anatomic asplenia (including sickle cell disease) and persistent complement component deficiency (including persons taking eculizumab [Soliris]) should receive MenB vaccine.
For children 2 months through 23 months of age, an age-appropriate series of meningococcal conjugate vaccine should be administered. If MenACWY-D (Menactra) is administered to a child with asplenia or HIV, it should be after 2 years of age and at least 4 weeks after the completion of all PCV13 doses.
A 2-dose primary series of either MenACWY should be administered to persons 2 years of age or older with asplenia or complement deficiency. Following the primary series of vaccine, a 3-year interval to the next dose is recommended for persons who received their previous dose at younger than 7 years. A 5-year interval is recommended for persons who received their previous dose at age 7 years or older.
Although MPSV4 is licensed, persons with asplenia or complement deficiency should be vaccinated with MenACWY-CRM or MenACWY-D rather than MPSV4.
Meningococcal serogroup B vaccines are licensed for persons 10-25 years of age (in Egypt from 2 months of age) and are recommended for persons 10 years of age or older (in Egypt from 2 months of age) for persons with high-risk conditions like functional or anatomic asplenia or persistent complement component deficiency.
To learn more about disease, vaccine and inserts press here.